DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Targeting B7x and B7-H3 as New Immunotherapies for Prostate Cancer
Technical Report,01 Sep 2015,31 Aug 2016
Albert Einstein College of Medicine Bronx United States
Pagination or Media Count:
We have made good progress during the current funding period. We established protein expression systems to generate human and mouse B7-H3 fusion proteins and human and mouse B7x fusion proteins. We then used these fusion proteins to immunize B7-H3 gene knock mice and B7x gene knock-out mice to generate monoclonal antibodies. We successfully generated 13 monoclonal antibodies to B7x and 6 monoclonal antibodies to B7-H3. After functional screen, we will find blocking monoclonal antibodies against B7x or B7-H3 for in vivo immunotherapy for prostate cancer. To further translate our mouse studies to clinical setting, we have started to generate humanized NSG mice for further immunotherapy with human prostate cancer lines and human immune system. In addition, we are testing how B7x and B7-H3 regulate T cell functions and MDSC development. Finally, we have recently discovered the newest immune checkpoint HHLA2 and shown HHLA2 was over-expressed in 3 out 9 human prostate cancer patients.
APPROVED FOR PUBLIC RELEASE